What the FDA labels say about taking them together
Darunavir and tenofovir disoproxil
Darunavir's FDA label of August 29, 2025 names tenofovir disoproxil in its drug interactions section, and tenofovir disoproxil's label names darunavir too. The tenofovir disoproxil label: “Monitor patients receiving VIREAD concomitantly with lopinavir/ritonavir, ritonavir-boosted atazanavir, or ritonavir-boosted darunavir for TDF-associated adverse reactions. …”
Check it at the source: the darunavir FDA label on DailyMed (effective August 29, 2025, Janssen Products LP); the tenofovir disoproxil FDA label on DailyMed (effective June 7, 2024, Aurobindo Pharma Limited).
What does the darunavir label say about tenofovir disoproxil?
Darunavir label, drug interactionsDrugs without Clinically Significant Interactions with PREZISTA No dosage adjustments are recommended when PREZISTA/ritonavir is co-administered with the following medications: atazanavir, dolutegravir, efavirenz, etravirine, nevirapine, nucleoside reverse transcriptase inhibitors (abacavir, emtricitabine, emtricitabine/tenofovir alafenamide, lamivudine, stavudine, tenofovir disoproxil fumarate, zidovudine), pitavastatin, raltegravir, ranitidine, or rilpivirine.
Source: FDA drug label (PREZISTA), Janssen Products LP, effective August 29, 2025 (SPL set 814301f9-c990-46a5-b481-2879a521a16f), via openFDA; the full label on DailyMed
What does the tenofovir disoproxil label say about darunavir?
Tenofovir disoproxil label, drug interactionsConcomitant Drug Class/Drug Name: HIV-1 Protease Inhibitors: atazanavir lopinavir/ritonavir atazanavir/ritonavir darunavir/ritonavir; Effect on Concentration b: ↓ atazanavir ↑ tenofovir; Clinical Comment: When coadministered with tenofovir disoproxil fumarate, atazanavir 300 mg should be given with ritonavir 100 mg. Monitor patients receiving tenofovir disoproxil fumarate concomitantly with lopinavir/ritonavir, ritonavir-boosted atazanavir, or ritonavir-boosted darunavir for TDF-associated adverse reactions. Discontinue tenofovir disoproxil fumarate in patients who develop TDF-associated adverse reactions.
Viread label (Gilead Sciences, Inc., February 18, 2025), drug interactionsConcomitant Drug Class/Drug Name: lopinavir/ritonavir atazanavir/ritonavir darunavir/ritonavir; Effect on Concentration ↑=Increase, ↓=Decrease: ↑ tenofovir; Clinical Comment: Monitor patients receiving VIREAD concomitantly with lopinavir/ritonavir, ritonavir-boosted atazanavir, or ritonavir-boosted darunavir for TDF-associated adverse reactions. Discontinue VIREAD in patients who develop TDF-associated adverse reactions.
Source: FDA drug label (Viread, NDA021356), Gilead Sciences, Inc., effective February 18, 2025 (SPL set 33fd6418-fbdc-42ca-a50d-ce2a476a5418), via openFDA
Source: FDA drug label (Tenofovir Disoproxil Fumarate), Aurobindo Pharma Limited, effective June 7, 2024 (SPL set a75c6be8-3719-4bb3-8a9e-06e5254d2a82), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Darunavir | Tenofovir disoproxil | |
|---|---|---|
| Labeled for | HIV | HIV, Hepatitis B |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.16 per tablet 600 mg tablet | $0.294 per tablet 300 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once